Kenalog

Triamcinolone Acetonide, the active ingredient in Kenalog, is a corticosteroid presented as an injectable suspension for intra‑articular and intramuscular use. It reduces inflammation and modulates immune responses in patients requiring local or systemic corticosteroid therapy.

GNH USA supplies Kenalog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kenalog (triamcinolone acetonide) is employed in the management of inflammatory and immune‑mediated conditions affecting joints, soft tissues and allergic responses. - Rheumatoid arthritis (intra‑articular): provides rapid reduction of joint swelling and pain. - Osteoarthritis (intra‑articular): improves joint function and decreases discomfort. - Bursitis and tendinitis (injection): alleviates localized inflammation and promotes recovery. - Severe allergic reactions (systemic injection): suppresses acute hypersensitivity and airway edema. - Dermatologic inflammatory disorders (intralesional): reduces lesion size and erythema.

Kenalog may cause a range of adverse reactions, from mild to severe, depending on dose, route and patient susceptibility.

Common Side Effects: - Injection site pain or irritation. - Transient flushing or warmth. - Mild headache. - Elevated blood glucose in diabetic patients. - Temporary increase in blood pressure. - Minor gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Significant adrenal suppression. - Osteonecrosis of the jaw. - Opportunistic infections. - Vision changes or cataract formation. - Tissue atrophy or depigmentation at injection site.

Kenalog should be used with caution in specific clinical situations and patient populations. - Assess infection risk: avoid use in active systemic infections. - Monitor glucose: patients with diabetes may need tighter glycemic control. - Evaluate bone health: prolonged therapy can affect bone mineral density. - Screen for ocular disease: consider ophthalmologic review for patients with glaucoma or cataracts. - Use lowest effective dose: limit frequency of intra‑articular injections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kenalog can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors (e.g., ketoconazole): may increase steroid exposure. - Live vaccines: risk of severe infection due to immunosuppression. - Anticoagulants (e.g., warfarin): may enhance bleeding risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive gastrointestinal irritation. - Diuretics: may exacerbate hypokalemia. - Antidiabetic agents: may require dose adjustment due to hyperglycemia.